Evaluating First-Line Chemotherapy Strategies in Anaplastic Thyroid Cancer: Insights from a German Multicenter Registry
Highlight
– This large German multicenter registry study compared first-line carboplatin/paclitaxel (CP) chemotherapy with other cytotoxic regimens in anaplastic thyroid cancer (ATC).
– No significant differences in progression-free or overall survival were observed between CP and other chemotherapy approaches.
– Age, lymph node, and distant metastasis were key prognostic factors; surgery conferred a survival benefit.
– Rapid molecular diagnostics remain essential for personalized approaches, as chemotherapy mainly serves as a bridging strategy to alternative treatments.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.